Big pharma freshens up
Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol.
Drug rejections hold steady in 2020
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
Radiotherapeutics remain in the deal-making frame
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
Wave waves goodbye to its first generation
The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
Go or no go? The FDA plays hardball
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
